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Protein Tyrosine Phosphatase 1B (PTP1B) inhibition is a
target in the treatment of type 2 Diabetes Mellitus, and as
such PTP1B inhibitors are in Phase II clinical trials. Pre-
viously our laboratory demonstrated that myeloid-specific
deletion of PTP1B (LysM PTP1B) results in an increase in
systemic IL-10 secretion and expression. In the current
work we investigated how PTP1B deficiency affects the
activation phenotype of murine macrophages in response
to inflammatory stimuli. We demonstrate that myeloid-
specific PTP1B deletion results in a decrease in expression
of MHC Class I, along with co-stimulatory molecules
CD80 and CD40. Interaction assays reveal a defect in
the cells’ ability to activate reporter B3Z T cells. Myeloid-
specific PTP1B deletion increases the percentage of
bone-marrow-derived-macrophages (BMDMs) positive for
IL-10 which is associated with a decrease in iNOS produc-
tion. Western blotting analysis demonstrated hyperphos-
porylation of ERK1/2 which has been suggested before to
improve access to the IL-10 promoter. This provides evi-
dence to suggest that myeloid-PTP1B deletion decreases
MHC Class I expression and peptide presentation through
an IL-10-dependent mechanism.
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